[ad_1]
Pfizer and BioNTech, which were already working together to develop mRNA-based flu vaccines, expect to produce 50 million doses of the covid vaccine (to protect 25 million people) this year and up to 1.3 billion doses next. year, Reuters reports.
The vaccine, called BNT162b2, is based on RNA messaging technology, which relies on artificial genes that can be generated and manufactured in a few weeks and produced on a large scale faster than conventional vaccines.
[ad_2]
The vaccine, called BNT162b2, is based on RNA messaging technology, which relies on artificial genes that can be generated and manufactured in a few weeks and produced on a large scale faster than conventional vaccines.
According to the contract with the United States government, the price is $ 39 for the two doses to be inoculated to a person for immunization against Sars-Cov-2.
BioNTech CEO Ugur Sahin said he was optimistic that the effect of the immunization would last for about a year, but said he was not sure.
Pfizer will seek an emergency authorization in the United States to vaccinate people between the ages of 16 and 85 in the coming weeks.
Vaccine trials began in April in Germany and in May in the United States.
